KORU Medical Systems (NASDAQ:KRMD) Stock Price Expected to Rise, B. Riley Financial Analyst Says

KORU Medical Systems (NASDAQ:KRMD) had its price target increased by equities research analysts at B. Riley Financial from $7.00 to $8.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. B. Riley Financial’s price objective would indicate a potential upside of 86.92% from the stock’s previous close.

Several other analysts also recently weighed in on the stock. Canaccord Genuity Group lifted their price objective on shares of KORU Medical Systems from $5.00 to $6.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of KORU Medical Systems in a research report on Thursday, January 22nd. Wall Street Zen upgraded shares of KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 12th. Craig Hallum reaffirmed a “buy” rating and set a $7.00 price target on shares of KORU Medical Systems in a report on Tuesday, January 13th. Finally, Lake Street Capital boosted their price objective on KORU Medical Systems from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, KORU Medical Systems has a consensus rating of “Moderate Buy” and an average price target of $6.50.

KORU Medical Systems Price Performance

Shares of NASDAQ KRMD opened at $4.28 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.48 and a quick ratio of 1.92. The firm has a market capitalization of $198.26 million, a PE ratio of -71.33 and a beta of 0.47. KORU Medical Systems has a 1-year low of $1.86 and a 1-year high of $6.61. The business’s fifty day moving average price is $5.10 and its two-hundred day moving average price is $4.80.

KORU Medical Systems (NASDAQ:KRMD) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.02) by $0.01. The company had revenue of $10.90 million during the quarter, compared to the consensus estimate of $10.90 million. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 16.04%. On average, research analysts expect that KORU Medical Systems will post -0.13 EPS for the current year.

Hedge Funds Weigh In On KORU Medical Systems

Institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. increased its stake in KORU Medical Systems by 24.8% during the 4th quarter. Invesco Ltd. now owns 27,873 shares of the company’s stock valued at $162,000 after buying an additional 5,546 shares during the period. Occudo Quantitative Strategies LP bought a new stake in shares of KORU Medical Systems during the 4th quarter worth about $127,000. Price T Rowe Associates Inc. MD lifted its stake in shares of KORU Medical Systems by 26.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,036 shares of the company’s stock worth $158,000 after acquiring an additional 5,649 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of KORU Medical Systems by 28.3% in the 4th quarter. Russell Investments Group Ltd. now owns 195,773 shares of the company’s stock worth $1,137,000 after acquiring an additional 43,215 shares during the period. Finally, Royal Bank of Canada boosted its holdings in shares of KORU Medical Systems by 8,719.9% in the fourth quarter. Royal Bank of Canada now owns 133,004 shares of the company’s stock valued at $773,000 after acquiring an additional 131,496 shares in the last quarter. Institutional investors own 58.60% of the company’s stock.

Key Headlines Impacting KORU Medical Systems

Here are the key news stories impacting KORU Medical Systems this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and maintained a “buy” rating, implying roughly an 87% upside from the current price — a meaningful vote of confidence from a major dealer. Benzinga
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” rating and set a $6.00 target (≈40% upside), adding further analyst support for upside to the stock. Benzinga
• Positive Sentiment: KORU received EU MDR certification for its Freedom60® infusion pump with prefilled syringe compatibility — clear regulatory progress that should aid European commercialization and recurring revenue potential. Las Vegas Sun
• Positive Sentiment: Q4 2025 results beat EPS expectations (loss of $0.01 vs. -$0.02 est.), reported ~20% revenue growth and positive adjusted EBITDA; management also initiated FY2026 guidance with revenue of $47.5M–$50.0M (roughly in line with consensus ~ $48.8M). These operational improvements support medium-term growth prospects. Business Wire – Q4 & Guidance
• Neutral Sentiment: Analysts and the company provided forward revenue guidance but EPS guidance detail was not clearly disclosed in public summaries; revenue range is encouraging but leaves some near-term visibility questions. Q4 Press Release / Slide Deck
• Negative Sentiment: KORU announced a CEO transition: long-time CEO Linda Tharby will retire June 30 and the board appointed Adam Kalberma as successor. Leadership changes introduce short-term execution risk and can pressure the stock until the market judges the new CEO. Business Wire – CEO Transition
• Negative Sentiment: Despite positives, KRMD still shows a negative net margin and negative ROE; valuation and profitability concerns may keep selling pressure, which likely explains why the stock is trading lower even after upgrades and regulatory wins.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.